paxilline has been researched along with everolimus in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bianco, C; Bianco, R; Ciardiello, F; Cipolletta, A; D'Amato, C; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Fulciniti, F; Marciano, R; Nappi, L; Raimondo, L; Rosa, R; Servetto, A; Veneziani, BM | 1 |
1 other study(ies) available for paxilline and everolimus
Article | Year |
---|---|
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
Topics: Actin Cytoskeleton; Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Everolimus; Hedgehog Proteins; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Micrometastasis; Nuclear Proteins; Paxillin; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Smoothened Receptor; Sunitinib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |